PARP Inhibitors in Ovarian Cancer

To the Editor: In the PRIMA (PRIMA/ENGOT-OV26/GOG-3012) trial conducted by Gonzalez-Martin et al. (Dec. 19 issue),(1) the test used to define homologous-recombination deficiency (HRD) was based on the sum of three scores that identify specific structural variations in the genome attributable to HRD.(2) In the absence of a standard test or marker of HRD, in previous studies, investigators created these scores using BRCA mutations and platinum sensitivity as surrogate markers of HRD to determine whether a sample had HRD. Scores were based on patterns of large-scale state transitions,(3) loss of heterozygosity,(4) and telomeric allele imbalance(5) that were associated with the . . .